GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies

GRO Biosciences Inc. presented successful proof of concept results in two pre-clinical programs representing potential breakthroughs in autoimmune disease and immunogenicity at this week’s Discovery On Target conference.

Scroll to Top